Inhibition of HIV-1 by a Lentiviral Vector with a Novel Tat-Inducible Expression System and a Specific Tropism to the Target Cells

Touraj Farazmandfar,^{1,2} Mohammad Reza Haghshenas,² and Majid Shahbazi,^{1,3,*}

¹Department of Molecular Medicine, Faculty of Advanced Medical Technologies, Golestan University of Medical Sciences, Gorgan, Iran; ²Molecular and Cell Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran; ³Medical Cellular & Molecular Research Center, Taleghani Children Hospital of Golestan University of Medical Sciences, Gorgan, Iran.

Today, lentiviral vectors are favorable vectors for RNA interference delivery in anti-HIV therapeutic approaches. Nevertheless, problems such as the specific recognition of target cells and uncontrolled expression of the transgene can restrict their use *in vivo*. Herein we present a new HIV-inducible promoter to express anti-HIV short hairpin RNA (shRNA) by RNA Pol II in mammalian cells. We likewise showed a novel third-generation lentiviral vector system with more safety and a specific tropism to the target cells. The new promoter, CkRhsp, was constructed from the chicken β -actin core promoter with the R region of HIV-1 long terminal repeat fused upstream of minimal hsp70 promoter. This system was induced by HIV-1 Tat, and activates transcription of two shRNAs against two conserved regions of HIV-1 transcripts produced in two steps of the virus life cycle. We also mimicked HIV-1 cell tropism by using the HIV-1 envelope in structure of third-generation lentiviral vector. The new fusion promoter efficiently expressed shRNA in a Tat-inducible manner. HIV-1 replication was inhibited in transient transfection and stable transduction assays. The new viral vector infected only CD4⁺ cells. CkRhsp promoter may be safer than other inducible promoters for shRNA-mediated gene therapies against HIV. The use of the wild envelope in the vector packaging system may provide the specific targeting T lymphocytes and hematopoietic stem cells for anti-HIV-1 therapeutic approaches *in vivo*.

INTRODUCTION

CONTROLLING THE HUMAN IMMUNODEFICIENCY virus (HIV) infection is a major challenge in both developed and underdeveloped countries. Although the drugs used in antiretroviral therapies have noticeably decreased the index of progression to the acquired immune deficiency syndrome (AIDS) in HIV-infected individuals, they are not without major side effects and significant problems. Pharmacokinetic differences between patients result in many drug-related toxicities. Drug failures for those on antiretroviral therapies occur as a result of viral resistance and other problems arising from a lasting regimen of chemotherapy.^{1–3} Therefore, there is a necessity to develop alternative therapies for the treatment of HIV-infected patients. These genetic-based therapies include oligonucleotide-based materials like small interfering RNA (siRNA), suicide genes, or transdominant negative proteins. Many of

these approaches have demonstrated promising results in limiting viral replication. Some of these genetic therapies have also progressed to clinical trial. However, a main limitation in designing anti-HIV therapeutic approaches is the ability of the virus to escape and become resistant to therapies. As a result, it is essential to develop strategies that can remarkably restrict the ability of the HIV to become resistant to therapy. One way it can be achieved by a combination of gene targeting different viral products or early/late steps in the viral life cycle or the RNA interference (RNAi) against a conserved region in virus transcripts. It can greatly reduce the probability of virus mutants' escape.^{4,5}

Posttranscriptional silencing strategies by RNAi are being used by many studies for the development of new strategies in antiviral therapies.^{6,7} RNAi mainly involves the introduction of siRNA, a short, double-stranded RNA molecule with 21–23

*Correspondence: Dr. Majid Shahbazi, Medical Cellular & Molecular Research Center, Taleghani Children Hospital of Golestan University of Medical Sciences, Bolv Janbazan Street, Gorgan 4916668197, Iran. E-mail: shahbazimajid@yahoo.co.uk

nucleotides and 3' overhang of two nucleotides, modified by the endoribonuclease Dicer. Dicer promotes the activation of the RNA-induced silencing complex that is essential for RNAi.^{8,9} The siRNA molecules can be transfected as synthetic double-stranded RNA or can be achieved by expression plasmids as separate sense and antisense strands. Another approach is the use of a short hairpin RNA (shRNA) 21–29 nucleotides long that can be processed to an siRNA molecule.^{10–12}

Replication-defective lentiviral vectors derived from HIV-1 have proven to be very potent to transduce both nonreplicating and replicating cells and long-term expression of the therapeutic transgene. These properties suggest the advantages of using these vectors for gene therapy. Today, lentiviral vectors are favorable vectors for RNAi delivery in anti-HIV therapeutic approaches.^{13,14} However, problems such as the specific recognition target cells and uncontrolled expression of the transgene can restrict their use *in vivo*.

To design selective inducible vectors, the HIV long terminal repeat (LTR) has been used as the promoter by several studies, to control transcription of antiviral RNAs and proteins in HIV-infected cells.^{15–19} The LTR promoter is strongly induced by Tat, a protein produced in early steps of HIV-1 life cycle. Tat binds to the transactivation response element (TAR), a stem-loop sequence at the 5' LTR of viral RNA.²⁰ Two known chimeric promoters on this approach are the LTR-hsp^{18,19} and the CK-TAR.^{21,22} The LTR-hsp was constructed from the full HIV-1 LTR and *Drosophila* minimal heat shock promoter 70 (Δ HSP), and was used to Tat-inducible expression of anti-HIV shRNA and protein. In this promoter, transcription from the Δ HSP element was controlled by the Tat protein attached to TAR in LTR and creates a precise transcriptional start site downstream of the LTR. This property could eliminate non-base-paired sequence in 5' of shRNA.¹⁸ The CK-TAR promoter was created when Han and colleagues²¹ found that LTR sequences other than TAR domain are not required for Tat transactivation. This promoter is composed of the core promoter of the chicken β -actin gene, for the binding of transcription factors, fused upstream of the viral TAR sequence. In comparison with LTR-hsp, the CK-TAR promoter could be safer with regard to vector mobilization and insertional mutagenesis that can occur with the virus LTR. However, the CK-TAR promoter cannot make a favorable transcriptional start site in shRNA expression approaches. It also had a relative basal activity in the absence of Tat, which reduces its competence in selective expression.²² Hence, both promoters may

not be safe or efficient enough in therapeutic approaches.

Given the above explanation, we decided to design a novel lentiviral delivery system to express anti-HIV shRNA against two conserved regions in the HIV-1 transcripts. To increase safety and neutralize vector mobilization, and also to obtain a favorable transcriptional start site in shRNA expression, we devised a Tat-inducible promoter in which chicken β -actin core promoter with the R region of HIV-1 LTR was fused upstream of minimal hsp70 promoter and it was named CkRhsp. We also mimicked HIV-1 cell tropism by using HIV-1 envelope in the structure of lentiviral vectors and investigated its anti-HIV activity *in vitro*.

MATERIALS AND METHODS

ShRNA design

In this study, two shRNAs were designed to target two highly conserved sites in the HIV-1 RNA sequence as previously reported.²³ These shRNAs included 28-nucleotide stem and a 9-base loop¹¹ (Fig. 1A). The first shRNA (T/R) targets Tat/Rev transcripts (early products in HIV-1 life cycle) in position 5547–5568 of the viral genome. The second shRNA (I/V) targets integrase/Vif transcripts (late products) in position 4622–4643 of the viral genome (Fig. 1B).

Vector constructions

The CkRhsp-shRNA cassettes were synthesized by using sequences of the 278 bp chicken β -actin core promoter (pbetaAct plasmid, ATCC, 37507), the 99 bp R region of HIV-1 LTR (pLenti6.2/GW

Figure 1. shRNA information. **(A)** The shRNA sequence with minimal polyadenylation. **(B)** The HIV-1 genome showing the positions of the two target sites. I/V and T/R shRNAs target the overlapping regions in integrase/Vif and Tat/Rev transcripts, respectively. shRNA, short hairpin RNA.

(Invitrogen) according to manufacturer's protocol. The cDNAs were then quantified in triplicate, using forward and reverse primers and Maxima SYBR Green Master Mix (Fermentas) in Bio-Rad iQ5 Real-Time PCR system (Bio-Rad, Munich, Germany). The shRNA expression was normalized against U6-snRNA endogenous control as previously described.²⁵ The relative expression was calculated using the $2^{-\Delta Ct}$ ($\Delta Ct = Ct$ of control gene – Ct of target gene).

Lentiviral vector production

A third-generation lentiviral vector system was used to produce transducing vectors as described by Yam et al.²⁶ HEK293T cells (ATCC, CRL-3216) were cultured to achieve the 90% confluency in a 100 mm culture dish. The cells were cotransfected with 15 μ g of transfer vector with the appropriate insert, 15 μ g of pLP1(Gag/Pol), 10 μ g of pLP2(Rev) (Invitrogen), and 5 μ g of pLP-Env (Fig. 2C), by the calcium phosphate precipitation protocol.²⁷ Eight hours posttransfection, the culture medium was replaced by the fresh medium. After 24 and 48 hr of transfection, the culture supernatants were harvested and pooled. Vector supernatant was collected from the three harvests and cleared by centrifugation at 250 g for 6 min at 4°C, and then filtered through a 0.45 μ m filter and concentrated by Lenti-X Concentrator kit (Clontech). The viral titer was determined by p24 level according to the ELISA kit's user guide (Clontech). Lentiviral vector titers ranged from 4×10^8 to 6×10^8 infectious units/ml.

Lentiviral vector transduction and HIV-1 challenge

To transduce the human T-cell line CEM (ATCC, CCL-119) and HEK293 cell line (as CD4-negative), 2×10^5 cells were plated in a 15 ml centrifuge tube containing 1 ml RPMI1640 medium. Lentiviral vectors were added to the tube in a multiplicity of infection (MOI) of 10 without polybrene. Twenty-four hours posttransduction, the cells were centrifuged and cultured in a fresh medium containing 8 μ g/ml of antibiotic blasticidin (Invitrogen) every 3 days. After 12 days, 10^6 live cells were infected with HIV-1 strain NL4-3 at an MOI of 0.001. The cells were then incubated overnight and washed three times with Hanks' balanced salt solution and cultured in the medium with 20% FBS. On days 3–18 after infection, the cell cultures were changed every 3 days, and the supernatant was collected for the HIV-1 p24 assay. Cell viability was also determined by the trypan blue staining. ShRNA expression was analyzed on all time points in cells transduced with the CkRhsp-T/R-I/V vector.

Statistical analysis

The differences between variables were identified by ANOVA test. Data analyses were performed by SPSS software version 17 (SPSS Inc., Chicago, IL). A p -value less than 0.05 was considered statistically significant.

RESULTS

The CkRhsp promoter expressed shRNA in a Tat-inducible manner

In this study, we constructed two types of plasmid vectors in which anti-HIV shRNAs are expressed from two Tat-inducible promoters by RNA polymerase II, the CkRhsp (novel promoter), and HIV-1 LTR (for comparison) (Fig. 2A). To test whether Tat made by HIV-1 could sufficiently induce inhibition from the CkRhsp promoter, the HEK293 cells are cotransfected with shRNA expression plasmids and a HIV-1 infectious clone (pNL4-3). HIV-1 gene expression was then measured by p24 assay on cell supernatants. Results in Fig. 3A show that the virus gene expression significantly decreased when cells were cotransfected with both shRNA vectors and pNL4-3 (plasmid containing *Tat* gene) ($p < 0.001$). In addition, the inhibition of virus gene expression by pLenti/CkRhsp plasmids was more efficient than that by the pLenti/LTR plasmid ($p = 0.015$) (Fig. 3A).

To investigate efficacy of the new promoter, we measured the level of mature siRNAs resulting from transfection. As shown in Fig. 3B, there is a considerable level of shRNA expression when cells were cotransfected with shRNA plasmids and pNL4-3, but not in cells transfected only with shRNA plasmids. Importantly, low expression of shRNAs in the absence of Tat protein (no pNL4-3) shows a very low basal activity of the CkRhsp promoter compared with the LTR promoter ($p < 0.001$). Moreover, shRNA expression by pLenti/CkRhsp plasmids was little more than that by the pLenti/LTR plasmid (Fig. 3B).

HIV-1 inhibition in transient transfection assay

To test pLenti vectors in a transient expression setting and also to investigate its potency against HIV-1, the HEK293 cells were cotransfected with the shRNA plasmids and pNL4-3. As results in Fig. 3A show, in day 3 posttransfection, there was an approximate 80–97% inhibition of HIV-1 replication by pLenti/CkRhsp-shRNA plasmids relative to pNL4-3 and irrelevant shRNA ($p < 0.001$). The level of inhibition mediated by pLenti/CkRhsp-T/R-I/V was significantly higher than that seen with pLenti/CkRhsp-T/R and pLenti/CkRhsp-I/V ($p = 0.23$).

Figure 3. siRNA expression driven by the RNA Pol II promoter inhibits HIV-1 gene expression. **(A)** HEK293 cells were cotransfected with proviral pNL4-3 and pLenti constructs and the p24 protein level was determined on day 3. HIV-1 gene expression was efficiently inhibited by shRNA constructs driven by both CkRhsp and LTR promoters. **(B)** The real-time PCR analysis of siRNAs extracted from HEK293 cells shows high expression in cells cotransfected with transfer vectors and pNL4-3 (as Tat producer). siRNA expression levels in no pNL4-3-transfected cells indicate that the basal activity of the LTR promoter is significantly higher compared with CkRhsp. All the data are from the three independent experiments. siRNA, small interfering RNA. Color images available online at www.liebertpub.com/hum

HIV-1 inhibition in stable transduction assay

The CEM cell line was stably transduced with vectors containing the CkRhsp-shRNA cassettes and wild envelope (Fig. 2B). The transduced cells were then challenged with HIV-1 strain NL4-3. At six time points, culture supernatants were obtained and were analyzed for p24 levels and expressed as a p24

chart. The percentage of live cells was also determined by trypan blue staining and demonstrated as a cell viability chart. As observed in Fig. 4A, our lentiviral vector can potentially infect CEM cells without chemical reagents such as polybrene.

Our results in Fig. 4A show that a strong virus inhibition was observed in cells transduced with

Figure 4. HIV-1 challenge assay. **(A)** CEM cells transduced with pLenti/CkRhsp-shRNA vectors were challenged with the HIV-1 NL4-3 strain. **(B)** Cells were stained with trypan blue and counted using hemocytometer at the indicated days. All the data are from the three independent experiments. Color images available online at www.liebertpub.com/hum

shRNA vectors relative to NL4-3 strains ($p < 0.001$). At 15–18 days postinfection, cells transduced with single-shRNA vectors showed viral replication as an increase in p24 level, whereas the dual-shRNA vectors decreased virus replication and increased cell viability percentage ($p = 0.021$) (Fig. 4).

Lentiviral vectors with wild envelope have a specific tropism to CD4+ cells

To investigate efficacy of novel vector in specific tropism to CD4+ cells, we have analyzed shRNA expression level in CEM (as CD4+) and HEK293 (as CD4-) cells transduced with CkRhsp-shRNA vectors. Our results in Fig. 5 show that shRNA was considerably expressed only in CEM cells and no expression was detected in HEK293 cells.

DISCUSSION

To avoid the side effects of chemotherapy and development of drug-resistant HIV-1 strains in the treatment of HIV-infected patients, there is a need to develop alternative therapeutic approaches such as gene therapy.⁴ The unique features of HIV-1 virus and the various mechanisms of pathogenesis involved in disease progression and ultimately death pose considerable problems in the design of effective gene therapeutic setting. Stable integration, high mutability of the viral genome, the tendency of virus to latency, and its accumulation in immunologically privileged cells such as brain are some of these

features.²⁸ Therefore, it is more appropriate that different stages of virus life cycle and multiple products be targeted for more effective therapy.

During the past decade, RNAi gene silencing has proven to be an efficient tool for disrupting specific genes' function and is considered as a potential antiviral agent in gene therapy strategies. Successful application of this novel technology *in vivo* requires vector development in the fields of safety and specific transducing target cells. An advantage of the RNAi-based therapies compared with protein-based approaches is lack of immunogenicity of the RNAi molecules.^{29,30} For the effective inhibition of HIV-1 replication with an RNAi-based gene therapy, the use of multiple shRNAs simultaneously and preferably targeting highly conserved sequences have been proposed.^{31–34} In most previous studies, the targets of siRNAs or shRNAs in HIV-1 transcripts are not in fact highly conserved, and only a few studies focused on targeting conserved HIV-1 sequences.^{23,35–38} As previously reported^{39,40} and our results at 15–18 days postinfection show (Fig. 4A), HIV-1 can escape from inhibition by mutations in sequences targeted by a single shRNA. We therefore decided to design two shRNAs for targeting two highly conserved regions in the HIV-1 genome in a dual-shRNA expression from a novel RNA polymerase II promoter.

There are potent advantages to utilizing RNA polymerase II in shRNA expression, including inducible transcription and tissue-specific promoters.¹² Several studies have focused on the use of HIV LTR for HIV induction of anti-HIV genes' expression.^{41,42} In the present study, we demonstrated an HIV-1-inducible shRNA promoter in which the chicken β -actin core promoter with the R region of HIV-1 LTR was fused upstream of the *Drosophila* minimal hsp70 promoter (Fig. 2A). It is already known that the full LTR other than TAR element is not necessary for Tat transactivation.²¹ In addition, the use of HIV LTR may increase the risks of vector mobilization and insertional mutagenesis, which may not be appropriate *in vivo* approaches. Therefore, we exchanged the U3 region in HIV LTR with a safer alternative promoter such as the chicken β -actin promoter for transcription of the TAR sequence, which may be more favorable for *in vivo* applications. The U5 region of HIV LTR is also removed. The U5 sequence contains sequences such as primer binding sites that are involved in reverse transcription.⁴³ With regard to this point, adding these sequences among the two LTRs in the vector genome (triple U5) may interfere with the efficient functioning of vectors in the target cells. As previously reported by Xia et al.,¹² the hsp70 promoter and HIV-1 LTR show considerable similarities in

Figure 5. Investigation of vector-specific tropism to CD4+ cells via siRNA expression analysis in transduced cell lines. siRNAs extracted from CEM and HEK293 cells were transduced with the CkRhsp-T/R-I/V vector and expression levels were determined by real-time PCR. All the data are from the three independent experiments. Color images available online at www.liebertpub.com/hum

transcription initiation. Both promoters are arrested by promoter-proximal pausing and are released by the Tat element (Fig. 2A). Hence, we decided to create a Tat-inducible promoter by fusing the minimal hsp70 promoter to downstream of the chicken β -actin core promoter and TAR element (Fig. 2A), in contrast to Unwalla et al.'s study,¹⁸ in which the hsp70 promoter had been attached to full-length LTR. In the CkRhsp promoter, transcription initiation from the hsp70 promoter is dependent on binding Tat to TAR element in its upstream. Therefore, the shRNA expression occurs only in HIV-1-infected cells containing the Tat protein. As is understood from the results of Fig. 3, the new chimeric promoter can efficiently help to minimize no-Tat basal activity and elimination of non-base-paired sequences of 5' end in shRNA expression. These results demonstrated that, unlike HIV LTR in the CkRhsp promoter, transcription initiating from the hsp70 can be more efficiently processed into an siRNA. Transcripts resulting from the HIV LTR would have an additional sequence (TAR and U5) at the 5' end of the sense strand that would reduce recognition and processing to mature siRNAs.^{12,18,19}

Compared with the previous studies that used VSVG-pseudotyped vector to cell transduction, a remarkable change in this work is to deliver anti-HIV shRNA constructs via a lentiviral vector with the HIV-1 envelope. This modification mimicked specific tropism to the target cells without using chemicals such as polybrene, which raises the chance of using

these vectors for *in vivo* approaches. As siRNA expression analysis in Fig. 5 shows, only CD4+ cells (CEM) were transduced by our new vector.

In summary, we have provided a novel third-generation lentiviral vector system to inhibit HIV-1 replication with specific features, including more safety, HIV-inducible, and specific targeting, one step closer to a treatment of the HIV-infected individuals. These experiments indicated that RNAi can be expressed by a Tat-inducible promoter other than the full HIV-1 LTR. The chimeric CkRhsp promoter, as well as LTR, can efficiently be induced by Tat, but with more safety, lower risk of LTR mobilization, and favorable start site in shRNA expression. RNAi is a potent antiviral agent in a gene therapy approach, specially expressing multiple shRNAs to target high conserved sequences from a single viral vector. The use of wild envelope in the vector packaging system may provide the specific targeting T lymphocytes and hematopoietic stem cells for anti-HIV-1 therapeutic approaches *in vivo*.

ACKNOWLEDGMENT

This study was supported by the Research and Technology Council of Golestan University of Medical Sciences (Grant No. 241756).

AUTHOR DISCLOSURE

No competing financial interests exist.

REFERENCES

- Rossi JJ, June CH, Kohn DB. Genetic therapies against HIV. *Nat Biotechnol* 2007;25:1444–1454.
- Deeks SG. Antiretroviral treatment of HIV infected adults. *BMJ* 2006;332:1489.
- Phillips AN, Gazzard BG, Clumeck N, et al. When should antiretroviral therapy for HIV be started? *BMJ* 2007;334:76–78.
- Li M-J, Bauer G, Michienzi A, et al. Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. *Mol Ther* 2003;8:196–206.
- Unwalla HJ, Rossi JJ. A dual function TAR Decoy serves as an anti-HIV siRNA delivery vehicle. *Virology* 2010;7:33.
- Haasnoot J, Berkhout B. Nucleic acids-based therapeutics in the battle against pathogenic viruses. *Handb Exp Pharmacol* 2009;(189):243–263.
- Spurgers KB, Sharkey CM, Warfield KL, et al. Oligonucleotide antiviral therapeutics: antisense and RNA interference for highly pathogenic RNA viruses. *Antiviral Res* 2008;78:26–36.
- Bernstein E, Caudy AA, Hammond SM, et al. Role for a bidentate ribonuclease in the initiation step of RNA interference. *Nature* 2001;409:363–366.
- Chendrimada TP, Gregory RI, Kumaraswamy E, et al. TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing. *Nature* 2005;436:740–744.
- Caplen NJ, Parrish S, Imani F, et al. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. *Proc Natl Acad Sci USA* 2001;98:9742–9747.
- Lee NS, Dohjima T, Bauer G, et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. *Nat Biotechnol* 2002;20:500–505.
- Xia H, Mao Q, Paulson HL, et al. siRNA-mediated gene silencing *in vitro* and *in vivo*. *Nat Biotechnol* 2002;20:1006–1010.
- Sachdeva G, D'Costa J, Cho JE, et al. Chimeric HIV-1 and HIV-2 lentiviral vectors with added safety insurance. *J Med Virol* 2007;79:118–126.
- Galimi F, Verma IM. Opportunities for the use of lentiviral vectors in human gene therapy. *Curr Top Microbiol Immunol* 2002;261:245–254.
- Humeau LM, Binder GK, Lu X, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. *Mol Ther* 2004;9:902–913.
- Snyder LL, Esser JM, Pachuk CJ, et al. Vector design for liver-specific expression of multiple interfering RNAs that target hepatitis B virus transcripts. *Antiviral Res* 2008;80:36–44.
- Park J, Nadeau PE, Mergia A. Activity of TAR in inducible inhibition of HIV replication by foamy virus vector expressing siRNAs under the control of HIV LTR. *Virus Res* 2009;140:112–120.
- Unwalla HJ, Li M-J, Kim JD, et al. Negative feedback inhibition of HIV-1 by TAT-inducible expression of siRNA. *Nat Biotechnol* 2004;22:1573–1578.
- Unwalla HJ, Li H-T, Bahner I, et al. Novel Pol II fusion promoter directs human immunodeficiency virus type

- 1-inducible coexpression of a short hairpin RNA and protein. *J Virol* 2006;80:1863–1873.
20. Jeang KT, Xiao H, Rich EA. Multifaceted activities of the HIV-1 transactivator of transcription, Tat. *J Biol Chem* 1999;274:28837–28840.
21. Han P, Brown R, Barsoum J. Transactivation of heterologous promoters by HIV-1 tat. *Nucleic Acids Res* 1991;19:7225–7229.
22. Sanghvi VR, Steel LF. Expression of interfering RNAs from an HIV-1 Tat-inducible chimeric promoter. *Virus Res* 2011;155:106–111.
23. Ter Brake O, Konstantinova P, Ceylan M, et al. Silencing of HIV-1 with RNA interference: a multiple shRNA approach. *Mol Ther* 2006;14:883–892.
24. Farazmandfar T, Khanahmad Shahreza H, Haghshenas MR, et al. Use of integrase-minus lentiviral vector for transient expression. *Cell J* 2012;14:76–81.
25. Janbabai G, Farazmandfar T, Khosravi S. An investigation on 10 micro RNAs in colorectal cancer as biomarkers to predict disease progression. *Adv Biol Res* 2013;7:144–119.
26. Yam PY, Li S, Wu J, et al. Design of HIV vectors for efficient gene delivery into human hematopoietic cells. *Mol Ther* 2002;5:479–484.
27. Kingston RE, Chen CA, Rose JK. Calcium phosphate transfection. *Curr Protoc Mol Biol Ed Frederick M Ausubel Al* 2003;Chapter 9:Unit 9.1.
28. Banerjee A, Li M-J, Bauer G, et al. Inhibition of HIV-1 by lentiviral vector-transduced siRNAs in T lymphocytes differentiated in SCID-hu mice and CD34+ progenitor cell-derived macrophages. *Mol Ther J Am Soc Gene Ther* 2003;8:62–71.
29. McManus MT, Sharp PA. Gene silencing in mammals by small interfering RNAs. *Nat Rev Genet* 2002;3:737–747.
30. Couzin J. Small RNAs make big splash. *Science* 2002;298:2296–2297.
31. Berkhout B. RNA interference as an antiviral approach: targeting HIV-1. *Curr Opin Mol Ther* 2004;6:141–145.
32. Ter Brake O, Berkhout B. A novel approach for inhibition of HIV-1 by RNA interference: counteracting viral escape with a second generation of siRNAs. *J RNAi Gene Silenc* 2005;1:56–65.
33. Lee NS, Rossi JJ. Control of HIV-1 replication by RNA interference. *Virus Res* 2004;102:53–58.
34. Haasnoot PCJ, Cupac D, Berkhout B. Inhibition of virus replication by RNA interference. *J Biomed Sci* 2003;10:607–616.
35. Lee S-K, Dykxhoorn DM, Kumar P, et al. Lentiviral delivery of short hairpin RNAs protects CD4 T cells from multiple clades and primary isolates of HIV. *Blood* 2005;106:818–826.
36. Chang L-J, Liu X, He J. Lentiviral siRNAs targeting multiple highly conserved RNA sequences of human immunodeficiency virus type 1. *Gene Ther* 2005;12:1133–1144.
37. Dave RS, Pomerantz RJ. Antiviral effects of human immunodeficiency virus type 1-specific small interfering RNAs against targets conserved in select neurotropic viral strains. *J Virol* 2004;78:13687–13696.
38. Han W, Wind-Rotolo M, Kirkman RL, et al. Inhibition of human immunodeficiency virus type 1 replication by siRNA targeted to the highly conserved primer binding site. *Virology* 2004;330:221–232.
39. Das AT, Brummelkamp TR, Westerhout EM, et al. Human immunodeficiency virus type 1 escapes from RNA interference-mediated inhibition. *J Virol* 2004;78:2601–2605.
40. Westerhout EM, Ooms M, Vink M, et al. HIV-1 can escape from RNA interference by evolving an alternative structure in its RNA genome. *Nucleic Acids Res* 2005;33:796–804.
41. Dropulić B, Hěrmánková M, Pitha PM. A conditionally replicating HIV-1 vector interferes with wild-type HIV-1 replication and spread. *Proc Natl Acad Sci USA* 1996;93:11103–11108.
42. Paik SY, Banerjee A, Chen CJ, et al. Defective HIV-1 provirus encoding a multitarget-ribozyme inhibits accumulation of spliced and unspliced HIV-1 mRNAs, reduces infectivity of viral progeny, and protects the cells from pathogenesis. *Hum Gene Ther* 1997;8:1115–1124.
43. Goldschmidt V, Rigourd M, Ehresmann C, et al. Direct and indirect contributions of RNA secondary structure elements to the initiation of HIV-1 reverse transcription. *J Biol Chem* 2002;277:43233–43242.

Received for publication March 4, 2015;
accepted after revision June 4, 2015.

Published online: June 12, 2015.